Hideyasu Matsuyama

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/290708/publications.pdf

Version: 2024-02-01

54 1,212 17
papers citations h-index

55 55 1752 all docs docs citations times ranked citing authors

33

g-index

#	Article	IF	CITATIONS
1	Elevated scrotal temperature, but not varicocele grade, reflects testicular oxidative stress-mediated apoptosis. World Journal of Urology, 2010, 28, 359-364.	1.2	156
2	Pathophysiology of varicocele in male infertility in the era of assisted reproductive technology. International Journal of Urology, 2012, 19, 538-550.	0.5	133
3	Gain of 5p15.33 Is Associated with Progression of Bladder Cancer. Oncology, 2007, 72, 132-138.	0.9	118
4	Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Gu�rin immunotherapy for carcinoma in situ of the bladder. Cancer Immunology, Immunotherapy, 2003, 52, 481-486.	2.0	83
5	Cotinine excretion and daily cigarette smoking in habituated smokers. Clinical Pharmacology and Therapeutics, 1979, 25, 555-561.	2.3	70
6	Polymorphisms of DNA repair genes are associated with renal cell carcinoma. Biochemical and Biophysical Research Communications, 2006, 342, 1058-1062.	1.0	57
7	Association of theBCRP C421A polymorphism with nonpapillary renal cell carcinoma. International Journal of Cancer, 2005, 117, 431-434.	2.3	51
8	Clinical significance of chromosome 8p, 10q, and 16q deletions in prostate cancer. Prostate, 2003, 54, 103-111.	1.2	49
9	Klinefelter syndrome: From pediatrics to geriatrics. Reproductive Medicine and Biology, 2019, 18, 140-150.	1.0	31
10	Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma. International Journal of Clinical Oncology, 2021, 26, 169-177.	1.0	28
11	Risk group stratification to predict recurrence after transurethral resection in Japanese patients with stage Ta and T1 bladder tumours: validation study on the European Association of Urology guidelines. BJU International, 2011, 107, 1598-1604.	1.3	24
12	Association of <i>TP53</i> and <i>MDM2</i> polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy. Cancer Science, 2009, 100, 2376-2382.	1.7	23
13	Antiâ€tumor efficacy of human antiâ€câ€met CARâ€T cells against papillary renal cell carcinoma in an orthotopic model. Cancer Science, 2021, 112, 1417-1428.	1.7	21
14	Direct and indirect effects of recombinant human granulocyte-colony stimulating factor on in vitro colony formation of human bladder cancer cells. Cancer Immunology, Immunotherapy, 1994, 38, 353-357.	2.0	20
15	Copy number aberrations using multicolour fluorescencein situhybridization (FISH) for prognostication in non-muscle-invasive bladder cancer (NIMBC). BJU International, 2014, 113, 662-667.	1.3	20
16	Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer. Journal of Clinical Medicine, 2019, 8, 489.	1.0	20
17	Cytokine-mediated antitumor effect of bacillus Calmette-Gu�rin on tumor cells in vitro. Cancer Immunology, Immunotherapy, 1994, 39, 249-253.	2.0	19
18	Clinical significance of lymph node dissection in renal cell carcinoma. Scandinavian Journal of Urology and Nephrology, 2005, 39, 30-35.	1.4	19

#	Article	IF	CITATIONS
19	Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer. International Journal of Clinical Oncology, 2014, 19, 946-954.	1.0	19
20	Diagnostic value of prostate-specific antigen-related parameters in discriminating prostate cancer. International Journal of Urology, 2000, 7, 409-414.	0.5	17
21	Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study. Japanese Journal of Clinical Oncology, 2019, 49, 1157-1163.	0.6	17
22	Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study. International Journal of Clinical Oncology, 2013, 18, 62-67.	1.0	15
23	Cytogenetic Analysis of False-Positive Mucosa by Photodynamic Diagnosis Using 5-Aminolevulinic Acid – Possible Existence of Premalignant Genomic Alterations Examined by in vitro Experiment. Oncology, 2009, 76, 118-125.	0.9	14
24	The effect of lanthanum carbonate on calciprotein particles in hemodialysis patients. Clinical and Experimental Nephrology, 2020, 24, 323-329.	0.7	14
25	A new risk stratification model for intravesical recurrence, disease progression, and cancer-specific death in patients with non-muscle invasive bladder cancer: the J-NICE risk tables. International Journal of Clinical Oncology, 2020, 25, 1364-1376.	1.0	14
26	Centrosome amplification as a putative prognostic biomarker for the classification of urothelial carcinomas. Human Pathology, 2011, 42, 1923-1930.	1.1	13
27	Risk for intravesical recurrence of bladder cancer stratified by the results on two consecutive UroVysion fluorescence in situ hybridization tests: a prospective follow-up study in Japan. International Journal of Clinical Oncology, 2020, 25, 1163-1169.	1.0	12
28	Effects of grade 1 varicocele detected in the pediatric age-group on testicular development. Journal of Pediatric Surgery, 2009, 44, 1995-1998.	0.8	11
29	Down-Grading of Ipsilateral Hydronephrosis by Neoadjuvant Chemotherapy Correlates with Favorable Oncological Outcomes in Patients Undergoing Radical Nephroureterectomy for Ureteral Carcinoma. Diagnostics, 2020, 10, 10.	1.3	10
30	Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2021, 27, 6164-6173.	3.2	10
31	Bladder cancer prospective cohort study on highâ€risk nonâ€rnuscle invasive bladder cancer after photodynamic diagnosisâ€assisted transurethral resection of the bladder tumor (BRIGHT study). International Journal of Urology, 2022, 29, 632-638.	0.5	10
32	Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy. Japanese Journal of Clinical Oncology, 2016, 46, 775-780.	0.6	9
33	Transcriptome Analysis to Identify Human Spermatogonial Cells from Sertoli Cell-Only Testes. Journal of Urology, 2020, 203, 809-816.	0.2	9
34	Granulocyte Colony-stimulating Factor may Promote Proliferation of Human Bladder Cancer Cells Mediated by Basic Fibroblast Growth Factor. Scandinavian Journal of Urology and Nephrology, 2003, 37, 286-291.	1.4	8
35	Expression of thymidine phosphorylase in human superficial bladder cancer. International Journal of Urology, 2005, 12, 29-34.	0.5	8
36	Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma. Japanese Journal of Clinical Oncology, 2020, 50, 214-220.	0.6	8

#	Article	IF	CITATIONS
37	Does Surgical Repair of Pelvic Prolapse Improve Patients' Quality of Life?. European Urology, 2004, 45, 213-218.	0.9	7
38	Running suture versus interrupted suture for vesicourethral anastomosis in retropubic radical prostatectomy: A randomized study. International Journal of Urology, 2015, 22, 271-277.	0.5	7
39	Genome-wide association study of genetic variations associated with treatment failure after intravesical bacillus Calmette–GuĀ©rin therapy for non-muscle invasive bladder cancer. Cancer Immunology, Immunotherapy, 2020, 69, 1155-1163.	2.0	7
40	Direct and indirect effects of human interferon? on renal cell carcinoma: a new in vitro assay system for evaluating cytokine-mediated antitumor effects. Cancer Immunology, Immunotherapy, 1993, 37, 84-88.	2.0	6
41	Association of <i>RASSF1A</i> genotype and haplotype with the progression of clear cell renal cell carcinoma in Japanese patients. BJU International, 2012, 110, 1070-1075.	1.3	6
42	Difference between Swedish and Japanese men in the association between AR CAG repeats and prostate cancer suggesting a susceptibility-modifying locus overlapping the androgen receptor gene. International Journal of Molecular Medicine, 2003, $11,529$.	1.8	5
43	BUBR1 overexpression predicts disease-specific survival after nephroureterectomy in patients with upper tract urothelial carcinoma. Japanese Journal of Clinical Oncology, 2016, 46, 754-761.	0.6	4
44	Could basic research shed light on false positivity in photodynamic diagnosis?. International Journal of Urology, 2012, 19, 695-696.	0.5	2
45	Pharmacokinetics of Neoadjuvant Axitinib Influenced the Efficacy in Patients With Advanced Renal Cell Carcinoma. Journal of Clinical Pharmacology, 2020, 60, 256-263.	1.0	2
46	Endoscopic laser treatment for urine leakage caused by an isolated calyx after robotâ€essisted partial nephrectomy. IJU Case Reports, 2021, 4, 343-346.	0.1	2
47	Novel prophylactic effect of doxifluridine in superficial bladder cancer. Scandinavian Journal of Urology and Nephrology, 2004, 38, 366-372.	1.4	1
48	Surgical Repair of Pelvic-Floor Prolapse: Lessons Learned from Longitudinal Follow-Up of Quality-of-Life Survey. Aktuelle Urologie, 2010, 41, S30-S33.	0.3	1
49	Receptor activator of the NFκB ligand system protects renal function during experimental renal ischemia-reperfusion in mice. Transplant Immunology, 2020, 58, 101263.	0.6	1
50	Mucinâ€producing urothelialâ€type adenocarcinoma of the prostate diagnosed after robotâ€assisted radical prostatectomy. IJU Case Reports, 2022, 5, 32-35.	0.1	1
51	Editorial Comment to Role of routine transurethral biopsy and isolated upper tract cytology after intravesical treatment of highâ€grade nonâ€muscle invasive bladder cancer. International Journal of Urology, 2012, 19, 994-994.	0.5	0
52	312 CAIX AND MCT4 SUPPRESSION DOWN-REGULATE THE CELL VIABILITY IN CLEAR CELL RENAL CELL CARCINOMA. Journal of Urology, 2013, 189, .	0.2	0
53	Recent Advance on Photodynamic Diagnosis (PDD) for Urological Malignancies. Nippon Laser Igakkaishi, 2010, 31, 400-405.	0.0	0
54	Clinical Significance of Centrosome Amplification in Bladder Cancer. Yamaguchi Medical Journal, 2010, 59, 9-15.	0.1	0